Blog
RSS FeedPosted by Michael Wonder on 15 Jan 2026
Ontario pioneers access to treatment for severe alopecia areata with Lilly's Olumiant
14 January 2026 - Eli Lilly Canada announced today that Ontario leads the way as the first province to add Olumiant ...
Posted by Michael Wonder on 14 Jan 2026
Affordable eczema drug Dupixent still out of reach for children
14 January 2026 - Children under 12 with severe eczema face $20,000 yearly costs for life changing treatment despite medical experts ...
Posted by Michael Wonder on 12 Jan 2026
PHARMAC funds treatment for rare disorders
12 January 2026 - PHARMAC will fund nitisinone for people with the rare disorders tyrosinaemia type 1 and alkaptonuria from ...
Posted by Michael Wonder on 11 Jan 2026
Health Minister ‘committed’ to listing weight loss drugs on PBS
9 January 2026 - ‘It’s an equity issue as well as a health issue from my perspective.’ ...
Posted by Michael Wonder on 08 Jan 2026
Cheaper medicines for children's inflammatory diseases, rare liver disease and multiple sclerosis
8 January 2026 - Australians living with a range of debilitating conditions including juvenile arthritis, rare liver disease and multiple ...
Posted by Michael Wonder on 02 Jan 2026
New Zealand Pharmaceutical Schedule - 1 January 2026
1 January 2026 - The January 2026 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Dec 2025
Schedule of Pharmaceutical Benefits - 1 January 2026
1 January 2026 - The January 2026 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 13 Dec 2025
Quebec becomes first province in Canada to list new subcutaneous Opdivo on public drug plan for solid tumour indications
11 December 2025 - The subcutaneous administration of the established immunotherapy could free up an estimated 30,000 hours of infusion ...
Posted by Michael Wonder on 09 Dec 2025
Saskatchewan adds Capvaxive to publicly funded adult immunisation program
8 December 2025 - Merck announced today that the province of Saskatchewan has added Capvaxive, a 21 valent pneumococcal conjugate vaccine, ...
Posted by Michael Wonder on 05 Dec 2025
New data on drug approvals and reimbursement recommendations in Canada
27 November 2025 - We have published new data about Canada’s pharmaceutical landscape, including data about drug submissions filed with ...
Posted by Michael Wonder on 05 Dec 2025
Cheaper multiple sclerosis and rare cancer medicines now on PBS
4 December 2025 - Australians living with multiple sclerosis and rare cancers will now have access to life-changing medicines thanks ...
Posted by Michael Wonder on 04 Dec 2025
High risk early breast cancer patients in Quebec left behind by recent INESSS recommendation
3 December 2025 - Quebec has the highest rate of breast cancer in Canada. The Government of Quebec recently endorsed lowering ...
Posted by Michael Wonder on 03 Dec 2025
New hope for rare cancer patients as first immunotherapy treatment subsidised
3 December 2025 - An immunotherapy treatment for a potentially disfiguring form of head and neck cancer has been added to ...
Posted by Michael Wonder on 02 Dec 2025
New Zealand Pharmaceutical Schedule - 1 December 2025
1 December 2025 - The December 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Nov 2025
Schedule of Pharmaceutical Benefits - 1 December 2025
1 December 2025 - The December 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...